新辅助治疗后人类表皮生长因子受体2阳性乳腺癌中人类表皮生长因子受体2的缺失：一例报告
Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report.
作者信息
Yu Jing, Li Nan-Lin
机构信息
Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shaanxi Province, China.
出版信息
World J Clin Cases. 2022 Jun 16;10(17):5923-5928. doi: 10.12998/wjcc.v10.i17.5923.
BACKGROUND
Human epidermal receptor-2 (HER-2) expression has been reported to be discordant between primary tumor and metastatic tissue.
CASE SUMMARY
We presented a case diagnosed with the HER-2+ breast cancer patient who exhibited changes in the expression of HER-2 receptors on tumour samples from surgical specimens obtained after neoadjuvant treatment (NAT) compared with initial biopsy. The patient underwent a HER-2-targeted therapy consequently, in spite of HER+ gene loss. After the surgery, the patient subsequently underwent endocrine therapy and radiotherapy.
CONCLUSION
Changes in HER-2 expression after NAT should be retested by physicians and pathologists before systemic treatment instead of avoiding further HER-2-targeted therapy, and we will perform immunohistochemical multiple-spot biopsy analyses of other important clinical issues to better define prognosis and tailor subsequent adjuvant therapy.
背景
据报道，原发性肿瘤与转移组织之间的人表皮受体2（HER-2）表达不一致。
病例摘要
我们报告了一例被诊断为HER-2阳性乳腺癌的患者，与初始活检相比，该患者在新辅助治疗（NAT）后获得的手术标本肿瘤样本上，HER-2受体表达出现了变化。因此，尽管HER+基因缺失，该患者仍接受了HER-2靶向治疗。术后，患者随后接受了内分泌治疗和放疗。
结论
在进行全身治疗前，医生和病理学家应重新检测NAT后HER-2表达的变化，而不是避免进一步的HER-2靶向治疗，并且我们将对其他重要的临床问题进行免疫组织化学多点活检分析，以更好地确定预后并制定后续辅助治疗方案。
Zotero 插件